Trang T Ly

List of Publications by Year
in descending order

62 papers	2,961 citations	147566 31 h-index	168136 53 g-index
62 all docs	62 docs citations	62 times ranked	1899 citing authors

#	Article	IF	Citations
1	Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment. Diabetes Technology and Therapeutics, 2022, 24, 18-25.	2.4	2
2	Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. Clinical Diabetes, 2022, 40, 168-184.	1.2	10
3	Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care, 2022, 45, 1907-1910.	4.3	28
4	How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the OmnipodÂ® 5 System. Diabetes Research and Clinical Practice, 2022, 190, 109998.	1.1	15
5	Patientâ€reported outcomes in a study of human regular Uâ€500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 240-244.	2.2	4
6	First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, 410-424.	2.4	52
7	Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. Diabetes Research and Clinical Practice, 2021, 174, 108735.	1.1	9
8	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care, 2021, 44, 1630-1640.	4.3	133
9	Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes. Journal of Diabetes Science and Technology, 2021, 15, 1195-1197.	1.3	0
10	Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes. Clinical Diabetes, 2021, 39, 72-79.	1.2	8
11	Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2020, 22, 174-184.	2.4	61
12	Human regular Uâ€500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study. Diabetes, Obesity and Metabolism, 2020, 22, 434-441.	2.2	28
13	Glycemic Control and Factors Impacting Treatment Choice in Tubeless Insulin Pump Users: A Survey of the T1D Exchange Glu Online Community. Journal of Diabetes Science and Technology, 2019, 13, 1180-1181.	1.3	4
14	Feasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting. Journal of Diabetes Science and Technology, 2019, 13, 1001-1007.	1.3	8
15	Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. Diabetes Technology and Therapeutics, 2019, 21, 356-363.	2.4	44
16	Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 265-272.	2.4	33
17	Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age. Journal of Diabetes Science and Technology, 2019, 13, 20-26.	1.3	34
18	Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technology and Therapeutics, 2018, 20, 257-262.	2.4	62

#	Article	IF	Citations
19	Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. Diabetes Technology and Therapeutics, 2018, 20, 335-343.	2.4	64
20	Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas. Journal of Diabetes Science and Technology, 2018, 12, 599-607.	1.3	21
21	The Importance of the Hawthorne Effect on Psychological Outcomes Unveiled in a Randomized Controlled Trial of Diabetes Technology. Journal of Diabetes Science and Technology, 2018, 12, 735-736.	1.3	14
22	Predictive hyperglycemia and hypoglycemia minimization: Inâ€home doubleâ€blind randomized controlled evaluation in children and young adolescents. Pediatric Diabetes, 2018, 19, 420-428.	1.2	19
23	Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology and Therapeutics, 2018, 20, 648-653.	2.4	29
24	Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 585-595.	2.4	39
25	Stabilization of glycemic control and improved quality of life using a shared medical appointment model in adolescents with type 1 diabetes in suboptimal control. Pediatric Diabetes, 2017, 18, 204-212.	1.2	26
26	Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes, 2017, 18, 348-355.	1.2	46
27	In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes. Pediatric Diabetes, 2017, 18, 332-339.	1.2	12
28	Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. Diabetes Care, 2017, 40, 359-366.	4.3	20
29	Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technology and Therapeutics, 2017, 19, 288-292.	2.4	46
30	Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. Diabetes Technology and Therapeutics, 2017, 19, 331-339.	2.4	56
31	Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care, 2017, 40, 1096-1102.	4.3	46
32	Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Diabetes Educator, 2017, 43, 223-232.	2.6	78
33	Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery. Diabetes Technology and Therapeutics, 2017, 19, 18-24.	2.4	120
34	Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet, The, 2017, 389, 369-380.	6.3	207
35	Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 527-532.	2.4	87
36	Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension. Pediatric Diabetes, 2017, 18, 422-427.	1.2	10

#	Article	IF	Citations
37	Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs). Sensors, 2017, 17, 161.	2.1	21
38	Continuous Glucose Sensor Survival and Accuracy Over 14 Consecutive Days. Diabetes Care, 2016, 39, e112-e113.	4.3	8
39	Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care, 2016, 39, 1143-1150.	4.3	95
40	Continuous Glucose Monitoring Adherence. Journal of Diabetes Science and Technology, 2016, 10, 627-632.	1.3	16
41	Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 543-550.	2.4	34
42	Day-and-Night Closed-Loop Control Using the Unified Safety System in Adolescents With Type 1 Diabetes at Camp. Diabetes Care, 2016, 39, e106-e107.	4.3	35
43	Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 1268-1276.	1.3	37
44	Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 429-435.	2.4	27
45	Prevention of Insulin-Induced Hypoglycemia in Type 1 Diabetes with Predictive Low Glucose Management System. Diabetes Technology and Therapeutics, 2016, 18, 436-443.	2.4	29
46	Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp. Diabetes Technology and Therapeutics, 2016, 18, 377-384.	2.4	44
47	Closed-loop control in type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 191-193.	5.5	1
48	Technology and Type 1 Diabetes: Closed-Loop Therapies. Current Pediatrics Reports, 2015, 3, 170-176.	1.7	4
49	The Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 80-85.	1.3	27
50	Effect of Acetaminophen on CGM Glucose in an Outpatient Setting. Diabetes Care, 2015, 38, e158-e159.	4.3	73
51	Effect of Lipohypertrophy on Accuracy of Continuous Glucose Monitoring in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, e166-e167.	4.3	17
52	Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp. Diabetes Care, 2015, 38, 1205-1211.	4.3	111
53	Accuracy Evaluation of Blood Glucose Monitoring Systems in Children on Overnight Closed-Loop Control. Journal of Diabetes Science and Technology, 2014, 8, 969-973.	1.3	10
54	Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp. Diabetes Care, 2014, 37, 2310-2316.	4.3	109

#	Article	IF	Citations
55	Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 2014, 15, 180-192.	1.2	129
56	A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes. Value in Health, 2014, 17, 561-569.	0.1	34
57	Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2013, 310, 1240.	3.8	367
58	Hypoglycemia Does Not Change the Threshold for Arousal from Sleep in Adolescents with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2012, 14, 101-104.	2.4	16
59	Analysis of Glucose Responses to Automated Insulin Suspension With Sensor-Augmented Pump Therapy. Diabetes Care, 2012, 35, 1462-1465.	4.3	47
60	Neurocognitive Outcomes in Young Adults With Early-Onset Type 1 Diabetes. Diabetes Care, 2011, 34, 2192-2197.	4.3	53
61	Improving Epinephrine Responses in Hypoglycemia Unawareness With Real-Time Continuous Glucose Monitoring in Adolescents With Type 1 Diabetes. Diabetes Care, 2011, 34, 50-52.	4.3	72
62	Impaired Awareness of Hypoglycemia in a Population-Based Sample of Children and Adolescents With Type 1 Diabetes. Diabetes Care, 2009, 32, 1802-1806.	4.3	70